Your Partner for Growth, Hybridan

Hybridan

Your Partner for Growth

Our passion is raising growth capital for exciting, fast growth companies that want to take their business to the next level. We raise capital for companies both listed and unlisted in the most efficient manner possible and pride ourselves as being one of the few consistently profitable broking firms in the City. This has been achieved through a highly disciplined approach when seeking to create both corporate and institutional relationships.

Equity Bottom-Up

<ul><li>A further two contracts worth a combined £111,000 were announced this morning by the Company, as the total revenue pipeline continues to build.</li><li>These contracts with a new UK-based biopharmaceutical client have been won by the recently established Biometrics services division.</li><li>The Physiomics team have delivered over 100 commercial projects for drug development clients, including but not limited to, Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics and Cancer Research UK.</li></ul>

A further two contracts worth a combined £111,000 were announced this morning by the Company, as the total revenue pipeline continues to build.These contracts with a new UK-based biopharmaceutical client have been won by the recently established Biometrics services division.The Physiomics team have delivered over 100 commercial projects for drug development clients, including but not limited to, Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics and Cancer Research UK.

Hybridan Research: Physiomics plc: Synergistic Services

<ul><li>A contract extension has been signed with an existing large pharma client.</li><li>This builds upon the contract awarded in June 2024 and uses Physiomics’s proprietary Virtual Tumour platform to model the client’s targeted oncology agents in combination with other modalities helping inform dose and scheduling decisions.</li><li> The contract extension continues this work and supports the client’s expansion into new oncology indications.</li></ul>

A contract extension has been signed with an existing large pharma client.This builds upon the contract awarded in June 2024 and uses Physiomics’s proprietary Virtual Tumour platform to model the client’s targeted oncology agents in combination with other modalities helping inform dose and scheduling decisions. The contract extension continues this work and supports the client’s expansion into new oncology indications.

Hybridan Research: Physiomics plc: Building Relationships

<ul>
<li>Good Morning, Physiomics PLC (PYC) announced a contract with a new UK client.</li>
<li>We have published research on this which is attached and a snapshot of the research is below.</li>
<li>The third new client in two months is announced as a contract is awarded for a project involving rheumatoid arthritis, which is a new therapeutic area for the Company.</li>
</ul>


Good Morning, Physiomics PLC (PYC) announced a contract with a new UK client.
We have published research on this which is attached and a snapshot of the research is below.
The third new client in two months is announced as a contract is awarded for a project involving rheumatoid arthritis, which is a new therapeutic area for the Company.


Hybridan Research: Physiomics plc: New client, new therapeutic area

<ul>
<li>Three contracts have been announced since the Interim report on 6 March and three peer reviewed scientific articles have been published so far this year.</li>
<li>It includes sales from new clients in new therapeutic areas, which not only builds our confidence in the anticipated 31.5% increase in revenue for YE June 2025, but is also positive for FY June 2026.</li>
<li>A contract was reported on 17 March with a brand-new client in the field of Antibody Drug Conjugates (ADCs).</li>
</ul>


Three contracts have been announced since the Interim report on 6 March and three peer reviewed scientific articles have been published so far this year.
It includes sales from new clients in new therapeutic areas, which not only builds our confidence in the anticipated 31.5% increase in revenue for YE June 2025, but is also positive for FY June 2026.
A contract was reported on 17 March with a brand-new client in the field of Antibody Drug Conjugates (ADCs).


iFOREX Financial Trading / Equity Bottom-Up

<ul>
<li>Updated 10th June: iFOREX Financial Trading, the fintech business with a proprietary online and mobile trading platform for multi-asset contracts for difference, announced that its proposed IPO onto the Main Market, which was expected to occur in late June, will be briefly delayed.</li>
<li>A routine thematic compliance inspection commenced earlier this year in the BVI, which was disclosed in the Company's Registration Document, requires additional time to enable finalisation ahead of the IPO.</li>
<li>The inspection process is close to completion and the Company anticipates only a short delay to the IPO timetable. </li>
</ul>


Updated 10th June: iFOREX Financial Trading, the fintech business with a proprietary online and mobile trading platform for multi-asset contracts for difference, announced that its proposed IPO onto the Main Market, which was expected to occur in late June, will be briefly delayed.
A routine thematic compliance inspection commenced earlier this year in the BVI, which was disclosed in the Company's Registration Document, requires additional time to enable finalisation ahead of the IPO.
The inspection process is close to completion and the Company anticipates only a short delay to the IPO timetable. 


Duplicate of Hybridan Small Cap Feast: 12/06/2025

United Kingdom

Physiomics plc develops computer simulation technology to understand and predict patient responses to pharmaceuticals.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Physiomics (PYC LN)

Hybridan Research: Physiomics plc: Synergistic Services

A further two contracts worth a combined £111,000 were announced this morning by the Company, as the total revenue pipeline continues to...

Hybridan

Hybridan Research: Physiomics plc: Building Relationships

A contract extension has been signed with an existing large pharma client. This builds upon the contract awarded in June 2024 and uses...

Hybridan

Hybridan Research: Physiomics plc: New client, new therapeutic area

Good Morning, Physiomics PLC (PYC) announced a contract with a new UK client. We have published research on this which is attached and a snapshot...

Hybridan

Hybridan Research: Physiomics plc

Three contracts have been announced since the Interim report on 6 March and three peer reviewed scientific articles have been published so far this...

Hybridan

Duplicate of Hybridan Small Cap Feast: 12/06/2025

A routine thematic compliance inspection commenced earlier this year in the BVI, which was disclosed in the Company's Registration Document,...

Hybridan

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)